Brief review: Nondepolarizing neuromuscular blocking drugs and critical illness myopathy

Michael J. Murray, Sorin J. Brull, Charles F. Bolton

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Purpose: Critically-ill patients who receive nondepolarizing neuromuscular blocking drugs (NMBDs) may be at risk of developing profound muscle weakness that may last for months after the NMBD is discontinued, especially when large cumulative doses of NMBDs and corticosteroids are co-administered to septic, mechanically ventilated patients. This review focuses on the etiology and clinical features of critical illness myopathy (CIM), summarizes specific risk factors for its development, and discusses strategies that might be used to attenuate or even prevent the development of this potentially devastating syndrome. Clinical features: The etiology of CIM is unknown. Whether it can develop in at-risk patients who undergo lengthy operations during which they receive NMBDs is also unknown. In some patients following exposure to NMBDs their motor systems are impaired secondary to loss of thick (myosin) filaments that render the muscle unexcitable to direct electrical stimulation, while the sensory system is spared. Management of patients who develop NMBD myopathy is supportive, consisting of nutritional support, physical therapy, and daily trials of decreased ventilatory support. Conclusion: Recent guidelines recommend that NMBDs be used in critically ill patients only when absolutely necessary, that the depth of muscle paralysis be monitored to avoid overdosing and metabolite accumulation, and that drug administration be curtailed periodically to allow interruption of sustained NMBD effect.

Original languageEnglish (US)
Pages (from-to)1148-1156
Number of pages9
JournalCanadian Journal of Anesthesia
Volume53
Issue number11
DOIs
StatePublished - Nov 2006

Fingerprint

Muscular Diseases
Critical Illness
Pharmaceutical Preparations
Muscles
Nutritional Support
Muscle Weakness
Myosins
Paralysis
Electric Stimulation
Adrenal Cortex Hormones
Guidelines

ASJC Scopus subject areas

  • Anesthesiology and Pain Medicine

Cite this

Brief review : Nondepolarizing neuromuscular blocking drugs and critical illness myopathy. / Murray, Michael J.; Brull, Sorin J.; Bolton, Charles F.

In: Canadian Journal of Anesthesia, Vol. 53, No. 11, 11.2006, p. 1148-1156.

Research output: Contribution to journalArticle

Murray, Michael J. ; Brull, Sorin J. ; Bolton, Charles F. / Brief review : Nondepolarizing neuromuscular blocking drugs and critical illness myopathy. In: Canadian Journal of Anesthesia. 2006 ; Vol. 53, No. 11. pp. 1148-1156.
@article{c34f4144d5484087889e433e08d3b84d,
title = "Brief review: Nondepolarizing neuromuscular blocking drugs and critical illness myopathy",
abstract = "Purpose: Critically-ill patients who receive nondepolarizing neuromuscular blocking drugs (NMBDs) may be at risk of developing profound muscle weakness that may last for months after the NMBD is discontinued, especially when large cumulative doses of NMBDs and corticosteroids are co-administered to septic, mechanically ventilated patients. This review focuses on the etiology and clinical features of critical illness myopathy (CIM), summarizes specific risk factors for its development, and discusses strategies that might be used to attenuate or even prevent the development of this potentially devastating syndrome. Clinical features: The etiology of CIM is unknown. Whether it can develop in at-risk patients who undergo lengthy operations during which they receive NMBDs is also unknown. In some patients following exposure to NMBDs their motor systems are impaired secondary to loss of thick (myosin) filaments that render the muscle unexcitable to direct electrical stimulation, while the sensory system is spared. Management of patients who develop NMBD myopathy is supportive, consisting of nutritional support, physical therapy, and daily trials of decreased ventilatory support. Conclusion: Recent guidelines recommend that NMBDs be used in critically ill patients only when absolutely necessary, that the depth of muscle paralysis be monitored to avoid overdosing and metabolite accumulation, and that drug administration be curtailed periodically to allow interruption of sustained NMBD effect.",
author = "Murray, {Michael J.} and Brull, {Sorin J.} and Bolton, {Charles F.}",
year = "2006",
month = "11",
doi = "10.1007/BF03022883",
language = "English (US)",
volume = "53",
pages = "1148--1156",
journal = "Canadian Journal of Anesthesia",
issn = "0832-610X",
publisher = "Springer New York",
number = "11",

}

TY - JOUR

T1 - Brief review

T2 - Nondepolarizing neuromuscular blocking drugs and critical illness myopathy

AU - Murray, Michael J.

AU - Brull, Sorin J.

AU - Bolton, Charles F.

PY - 2006/11

Y1 - 2006/11

N2 - Purpose: Critically-ill patients who receive nondepolarizing neuromuscular blocking drugs (NMBDs) may be at risk of developing profound muscle weakness that may last for months after the NMBD is discontinued, especially when large cumulative doses of NMBDs and corticosteroids are co-administered to septic, mechanically ventilated patients. This review focuses on the etiology and clinical features of critical illness myopathy (CIM), summarizes specific risk factors for its development, and discusses strategies that might be used to attenuate or even prevent the development of this potentially devastating syndrome. Clinical features: The etiology of CIM is unknown. Whether it can develop in at-risk patients who undergo lengthy operations during which they receive NMBDs is also unknown. In some patients following exposure to NMBDs their motor systems are impaired secondary to loss of thick (myosin) filaments that render the muscle unexcitable to direct electrical stimulation, while the sensory system is spared. Management of patients who develop NMBD myopathy is supportive, consisting of nutritional support, physical therapy, and daily trials of decreased ventilatory support. Conclusion: Recent guidelines recommend that NMBDs be used in critically ill patients only when absolutely necessary, that the depth of muscle paralysis be monitored to avoid overdosing and metabolite accumulation, and that drug administration be curtailed periodically to allow interruption of sustained NMBD effect.

AB - Purpose: Critically-ill patients who receive nondepolarizing neuromuscular blocking drugs (NMBDs) may be at risk of developing profound muscle weakness that may last for months after the NMBD is discontinued, especially when large cumulative doses of NMBDs and corticosteroids are co-administered to septic, mechanically ventilated patients. This review focuses on the etiology and clinical features of critical illness myopathy (CIM), summarizes specific risk factors for its development, and discusses strategies that might be used to attenuate or even prevent the development of this potentially devastating syndrome. Clinical features: The etiology of CIM is unknown. Whether it can develop in at-risk patients who undergo lengthy operations during which they receive NMBDs is also unknown. In some patients following exposure to NMBDs their motor systems are impaired secondary to loss of thick (myosin) filaments that render the muscle unexcitable to direct electrical stimulation, while the sensory system is spared. Management of patients who develop NMBD myopathy is supportive, consisting of nutritional support, physical therapy, and daily trials of decreased ventilatory support. Conclusion: Recent guidelines recommend that NMBDs be used in critically ill patients only when absolutely necessary, that the depth of muscle paralysis be monitored to avoid overdosing and metabolite accumulation, and that drug administration be curtailed periodically to allow interruption of sustained NMBD effect.

UR - http://www.scopus.com/inward/record.url?scp=33751054939&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33751054939&partnerID=8YFLogxK

U2 - 10.1007/BF03022883

DO - 10.1007/BF03022883

M3 - Article

C2 - 17079642

AN - SCOPUS:33751054939

VL - 53

SP - 1148

EP - 1156

JO - Canadian Journal of Anesthesia

JF - Canadian Journal of Anesthesia

SN - 0832-610X

IS - 11

ER -